OBJECTIVES: Cardiovascular disease (CVD) is the leading cause of death globally and poses a substantial financial burden to healthcare systems. Evidence of the impact of CVD beyond the burden on healthcare systems is scarce. Inclisiran is a novel LDL-C lowering therapy expected to reduce the occurrence of cardiovascular events. The aim of this study was to estimate the health and socioeconomic benefits of introducing inclisiran using localized population health approaches across 15 countries.

METHODS: A Markov model was developed and adapted to each country to simulate the incremental health gains (avoided CV events and CV deaths) due to introducing inclisiran treatment for patients with pre-existing atherosclerotic CV disease aged 50 years and older. The potential health gains were translated into socioeconomic effects addressing paid work (absenteeism, presenteeism, return to work) and unpaid work (everyday activities such as cooking or cleaning). The resulting hours of gained productivity were monetized according to gross value added. Efficacy/effectiveness data and transition probabilities were derived from clinical trials. Country-specific economic data as employment rates were taken from official country-specific statistics.

RESULTS: During a period of 10 years, over 885 thousand CV events (including almost 240 thousand death cases) could be avoided for the assumed 2.39 million patients reached within the considered population health initiatives. The total societal value, defined as incremental benefit in paid and unpaid work productivity, amounts to 34 billion €.

CONCLUSIONS: The results demonstrate the potential health and socioeconomic value of inclisiran under a large-scale intervention across all analyzed countries. This highlights the importance to treat CV disease and generates understanding of health as an asset and a source of social and economic stability that supports policy decision makers to invest in population health management.